ExpressPoints Melanoma: Expert Guidance and Resources to Optimize Care Along the Treatment Continuum

Download this short summary slideset of key takeaways from a live CCO Webinar focused on current management of patients with high-risk resectable or metastatic melanoma.

Michael A. Davies, MD, PhD
Ahmad Tarhini, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 471 KB
Released: November 6, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bristol-Myers Squibb
Novartis Pharmaceuticals Corporation

Related Content

Part 2 of KEYNOTE-054 trial of adjuvant pembrolizumab vs placebo in high-risk stage III melanoma from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 10, 2021

5-year update of the COLUMBUS trial of encorafenib + binimetinib in BRAF V600-mutant melanoma from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 10, 2021

ABC study of nivolumab plus ipilimumab update at 5 years in patients with melanoma brain metastases from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 10, 2021

LEAP 004 trial update on lenvatinib + pembrolizumab in patients with advanced melanoma and progression on anti-PD-1/PD-L1 therapy from ASCO 2021 reported by Clinical Care Options (CCO)

Released: June 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue